MENU

Virtuoso Surgical: FDA de novo authorisation for bladder cancer robot

Medical Device Network USA
Overview
Virtuoso Surgical has received FDA de novo authorisation for its Virtuoso Endoscopy System, the first device in a new classification of electromechanical surgical systems for endoluminal procedures. The system enables en bloc resection of bladder tumours to improve diagnostic staging, with a planned US launch at leading urology centres in 2027.
In Depth

Key Findings

The US Food and Drug Administration (FDA) has granted de novo authorisation to Virtuoso Surgical for its endoscopic robot designed for the intact (en bloc) removal of bladder tumours. This authorisation establishes a new FDA classification for electromechanical surgical systems used in endoluminal surgical procedures. The system previously received breakthrough device designation in September 2025.

Technical Details

The Virtuoso Endoscopy System utilizes a rigid endoscope equipped with two needle-sized robotic arms at the tip. These arms translate the surgeon’s hand motions from a console to provide two-handed dexterity within the urethra. One arm is dedicated to lifting and retracting tumour tissue, while the second arm performs the dissection beneath the tissue.

In the VIABLE study (NCT06940648) conducted at The Chinese University of Hong Kong, the system demonstrated high efficacy in obtaining tissue samples. In the first 20 patients, detrusor muscle was present in 94% of removed lesions. This result exceeds the study’s 60% performance goal and the median rate of approximately 70% typically reported in conventional transurethral resection of bladder tumour (TURBT) therapy.

Background & Context

Bladder cancer affected over 600,000 cases worldwide in 2022. While TURBT has been the historical standard of care—often followed by immunotherapy—bladder cancers frequently recur and require lifelong monitoring. The presence of the detrusor muscle in removed specimens is critical for pathologists to determine the cancer stage.

Significance & Outlook

By enabling en bloc resection, the system provides better tissue specimens for clearer diagnosis and staging compared to conventional methods. Virtuoso Surgical intends to launch the system in the US at leading urology centres in 2027. This enters a broader robotic surgery market that GlobalData forecasts will grow from a valuation of $12.8bn in 2025 to $23.6bn by 2035, representing a CAGR of 6.3%.

Source: https://finance.yahoo.com/healthcare/articles/virtuoso-surgical-bladder-cancer-resection-171510892.html

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.

  • Your email and selected fields are used only to deliver the newsletter.
  • We never share your information with third parties.
  • You can unsubscribe anytime via the link in each email.

See our Privacy Policy for details.

Takes about a minute · Unsubscribe anytime

Published by Troy-Technical, an independent site run by one engineer with a career in materials development.
About the author / Contact info@troy-technical.jp
Let's share this post !

Author of this article

TOC